Navigation Links
Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease

Presentation of Final Phase I Monthly Implant and Phase IIa Daily Oral Results

LAUSANNE, Switzerland, June 11, 2007 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, presented final results of two Debio 9902 (formerly ZT-1) studies for the treatment of Alzheimer's disease (AD) at the Alzheimer's Association International Conference on the Prevention of Dementia, in Washington, DC:

- The phase I monthly sustained release implant study showed that Debio 9902 was well tolerated after repeated doses up to 15mg/per month and there were no safety concerns.

- The phase IIa once-daily oral study for a treatment period of 9 months showed that Debio 9902 was safe and effective in the treatment of moderate AD.

In a phase I study, healthy volunteers were administered once monthly subcutaneous injections of Debio 9902 SR implants up to 15mg. Sustained levels of Huperzine A (Hup A), the active metabolite of Debio 9902, were observed up to four weeks and Debio 9902 was well tolerated.

In a phase IIa study with the oral formulation of Debio 9902 in mild to moderate AD patients, improvements were observed on 3 efficacy scales, the assessment cognitive sub-scale (ADAS-cog), the Mini mental state examination (MMSE) and the Neuropsychiatric inventory questionnaire (NPI-Q). The study included a randomized part which lasted 3 months and which was followed by an additional 6 month open label part. The efficacy shown with the oral formulation, the good safety profile and the sustained release of Debio 9902 implants over one month have led to an ongoing phase II 'BRAINz' study in AD patients.

"The continuous release of Debio 9902 SR implants provides a new treatment alternative with the potential for better tolerance through a progressive, steady release of the active compound, therefore increasing p atient compliance and efficacy," said David Wilkinson, MARC, Moorgreen Hospital, Southampton, England and Principal Investigator in the United Kingdom.

About 'BRAINz'

'BRAINz' (Better Recollection for Alzheimer's patients with ImplaNts of ZT-1) is a phase II, double blind, double dummy clinical trial with Debio 9902 SR. The study will measure the safety and efficacy of Debio 9902 SR implants, in comparison to oral donepezil. The 'BRAINz' study is registered on www.clinicaltrials.gov.

About Debio 9902

Debio 9902 is a novel acetylcholinesterase (AchE) inhibitor that is transformed non-enzymatically into its active compound: Hup A. Hup A has been used in China for centuries to treat distinct disorders such as memory loss, schizophrenia and hypertension, and is widely used in North America and Europe as a food additive to enhance cognition and neuroprotection. The dual mode of action of Debio 9902 as an N-methyl-D-aspartate receptor antagonist and an AChE inhibitor, positions it as a third generation anti-Alzheimer's product by improving the general condition and cognitive functions of affected patients as well as having the potential of being a neuroprotectant. A compound with neuroprotective properties to complement the cholinergic effect, could potentially reduce the progression of AD. Debiopharm is seeking a partner for further development and commercialisation of Debio 9902.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit: www.debiopharm.com.

CONTACT: Debiopharm S.A. Contacts: Kim Bill, VP, Business Development &Licensing, Tel.: +41-(0)21-321-01-11, Fax: +41-(0)21-321-01-69,; Additional Media Contacts, In London, Maitland, BrianHudspith, Tel: +44-(0)20-7379-5151, ; In New York,Russo Partners, LLC, Wendy Lau, Tel: +1-212-845-4272, Fax: +1-212-845-4260, kbill@debiopharm.com bhudspith@maitland.co.uk wendy.lau@russopartnersllc.com

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
(Date:9/5/2017)... 2017  Just 18 months after its February 2016 ... announce the appointment of three new senior people to ... Dominic Jones-Phillips and James Wright bring ... Tammy Wynne joins as ... writers. She has over ten years, experience in global ...
Breaking Medicine Technology:
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... groceries, wearable, and more products at customers’ doorstep. According to Smart Mart, customers ... Mart has stated to offer wearable, and customers can find clothing at discounted ...
(Date:9/22/2017)... ... September 22, 2017 , ... Global Lyme Alliance ... research, education and awareness, today announced the appointment of Timothy J. Sellati, Ph.D. ... Sellati has more than 20 years of research experience with Lyme and other ...
(Date:9/21/2017)... ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery Center ... pleased to announce that Plastic Surgeon Kiranjeet Gill has been awarded as one of ... an annual award that was started in 2003 to salute young achievers in Southwest ...
(Date:9/21/2017)... ... September 21, 2017 , ... SABRE is raising awareness about personal safety ... the end of November. , The Chicago, Illinois, based self-defense brand has been waiting ... about the ease of taking their personal safety into their own hands. , The ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, Keeping Up ... , In the competitive world of drug and device marketing and promotion, drug ... FDA rules. , The FDA has issued two draft guidances that are the ...
Breaking Medicine News(10 mins):